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There is evidence that neuropeptides, especially the
opiate receptor agonists, are involved in wound healing.
We have previously observed that b-endorphin, the en-
dogenous ligand for the l-opiate receptor, stimulates
the expression of cytokeratin 16 in a dose-dependent
manner in human skin organ cultures. Cytokeratin 16
is expressed in hyperproliferative epidermis such as
psoriasis and wound healing. Therefore we were inter-
ested to study whether epidermal l-opiate receptor ex-
pression is changed at the wound margins in acute and
chronic wounds. Using classical and confocal micro-
scopy, we were able to compare the expression level of
l-opiate receptors and the in£uence of b-endorphin on
transforming growth factor b type II receptor in organ
culture. Our results show indeed a signi¢cantly de-
creased expression of l-opiate receptors on keratino-
cytes close to the wound margin of chronic wounds
compared to acute wounds. Additionally b-endorphin
upregulates the expression of transforming growth fac-
tor b type II receptor in human skin organ cultures.
These results suggest a crucial role of opioid peptides
not only in pain control but also in wound healing.
Opioid peptides have already been used in animal mod-
els in treatment of wounds; they induce ¢broblast pro-
liferation and growth of capillaries, and accelerate the
maturation of granulation tissue and the epithelization
of the defect. Furthermore opioid peptides may ¢ne-
tune pain and the in£ammatory response while healing
takes place. This new knowledge could potentially be
used to design new locally applied drugs to improve
the healing of painful chronic wounds. Key words: b-en-
dorphin/chronic and acute wounds/cytokeratin 16/epidermis/
7-opiate receptor/TGF-b receptor II/wound healing. J Invest
Dermatol 120:145 ^152, 2003
O
pioid peptides are produced by neurons in the
central and peripheral nervous system. Cells from
other organs are also able to produce and secrete
opioid peptides, however, such as enkephalins
and endorphins. Several types of cells in the skin,
including immune cells and keratinocytes, produce opioid pep-
tides. These endogenous opioid peptides interact directly with
opiate receptors in skin located on immune cells and nociceptive
nerve endings (Nissen et al, 1997). Furthermore we have recently
shown that functionally active m-opiate receptors are present on
human epidermal keratinocytes (Bigliardi et al, 1998). The m-opi-
ate receptor is expressed in all layers of the epidermis, but it is
more pronounced in the basal and suprabasal layers of epidermis.
The functional activity of these opiate receptors in human epider-
mis was studied using skin culture experiments. Results revealed
an upregulation of cytokeratin 16 (CK16) and a downregulation
of the m-opiate receptor in epidermis after incubation with the
endogenous ligand b-endorphin. This e¡ect of b-endorphin was
inhibited after incubation together with the m-opiate receptor an-
tagonist naltrexone (Bigliardi-Qi et al, 2000). CK16 is not ex-
pressed in normal skin, but appears in the suprabasal, di¡erentiat-
ing compartment of the epidermis during wound healing and
hyperproliferative skin diseases such as psoriasis and skin cancer
(Gerritsen et al, 1997). Therefore the upregulation of CK16 shows
the direct link of the m-opiate receptor system in wound healing.
There are several indications that neuropeptides are involved in
wound healing as well. Of special interest is proopiomelanocor-
tin (POMC). POMC is the precursor of adrenocorticotropin, b-
endorphin, melanocyte stimulating hormone, and lipotropin.
POMC products were consistently detected (10 of 11 cases)
in the keratinocytes and mononuclear cells at keloid lesions
(Slominski et al, 1993). It has been suggested that POMC products
may accumulate locally in lesional skin, representing a novel cu-
taneous response to injury, and that these products are produced
in situ by human skin. POMC products are also powerful modu-
lators of the immune system.There are additional indications that
opiate receptor agonists not only are present in wound £uid of
burn wounds (Soledad Cepeda et al, 1993) but also promote
wound healing (Kohl et al, 1989).Therefore we studied the expres-
sion of m-opiate receptor in epidermis at the wound margins,
especially to determine if the opiate receptor expression on kera-
tinocytes is di¡erent in chronic and acute wounds.We were addi-
tionally interested to investigate whether the expression of
receptors of growth factors crucial in wound healing are a¡ected
by the opiate receptor system. One of the most important factors
in wound healing is the transforming growth factor b (TGF-b
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receptor system, especially TGF-b type II receptor, a transmem-
brane serine/threonin kinase. The TGF-b type II receptor is ex-
pressed in regenerating epithelial cells of acute wounds and in
epithelial cells at the wound margin of chronic wounds and plays
an important role in wound healing.
MATERIALS AND METHODS
Preparation of human skin organ cultures for measuring TGF-b
type II receptor and CK16 expression after exposure to b-
endorphin The method of functional assays with skin organ cultures
was adapted from Paus et al (1994) and described in our previous paper
(Bigliardi-Qi et al, 2000). Brie£y skin grafts of about 0.5 mm thickness
were obtained by a dermatome from the upper leg of an individual. To
standardize the tissue volume and thereby the cell mass of cultured skin
fragments, only punches with 4 mm diameter were used. Several
randomized 4 mm skin punches per experimental group were placed on
AnocellTM 10 mm tissue culture inserts (Nunc, Life Technologies,
Rockville, MD). These inserts were put in a NunclonTM 24-well plate
containing 2 ml Dulbecco’s modi¢ed Eagle’s medium (DMEM with
Glutamax-I, Life Technologies) supplemented with 10% fetal bovine
serum and 50 mg per ml gentamicin (Life Technologies). After addition of
serial dilutions of the speci¢c endogenous m-opiate receptor agonist b-
endorphin (Sigma, St. Louis, MO), the organ cultures were incubated for
48 h at 371C in 5% CO2 and 100% humidity. As control we incubated skin
organ cultures in the culture medium only. At the end of the incubation
period the organ culture pieces were ¢xed in 4% formaldehyde and
embedded in para⁄n for use in immunohistochemistry. The
immunohistochemistry was performed as described above. The primary
antibodies were a mouse anti-CK16 antibody (NCL-CK16, Novocastra
Laboratories, Newcastle, U.K.) and a rabbit anti-TGF-b type II receptor
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) in separate
experiments. The binding was detected using the StrAviGen Super
SensitiveTM kit (BioGenex Laboratories, San Ramon, CA), which uses
biotinylated and alkaline phosphatase bound antibody. Naphthol red was
used to detect the alkaline phosphatase. In order to compare directly
the skin samples exposed to serial dilutions of b-endorphin, the
immunohistochemistry experiments in one series were performed
simultaneously in the same manner. The quanti¢cation of the
immunohistochemical staining with alkaline phosphatase was performed
as described below.
Staining of l-opiate receptor on para⁄n-embedded biopsies of
acute and chronic wounds with alkaline phosphatase First we
searched the database of the Dermatology Department of the University
of Basel for biopsies of chronic and acute wounds. Fifteen patient samples
were analyzed with alkaline phosphatase color staining. Six patient samples
were analyzed with £uorescence labeling. The para⁄n-embedded skin
biopsies were cut into 4 mm sections. The sections were dried overnight at
371C and depara⁄nized with xylol, ethanol (100%, 96%, 90%, 80%, 70%,
50%), distilled H2O, and phosphate-bu¡ered saline (PBS) (pH 7.0^7.2).
The immunohistochemistry method was modi¢ed from our previous
method (Bigliardi-Qi et al, 2000). Brie£y, the sections were microwave
treated in sodium nitrate bu¡er for 10 min at 951C and then blocked with
PBS with 5% normal goat serum for 1 h. The primary rabbit anti-m-opiate
receptor antibody (Diasorin, Stillwater, MN) was added and left overnight
at 41C. The binding was detected using the StrAviGen Super Sensitive kit,
which uses biotinylated and alkaline phosphatase bound antibody.
Naphthol red was used to detect the alkaline phosphatase, and Mayer’s
acid hematoxylin solution, containing sodium iodate, alaun, and
hematoxylin, was used as counterstain. The negative controls were the
sections that were not exposed to primary antibody. In order to compare
the skin samples directly the immunohistochemistry experiments in one
series were performed simultaneously in the same manner.
Quanti¢cation of immunohistochemical staining with alkaline
phosphatase The intensities of the expression of m-opiate receptor were
quanti¢ed using a digital CCD color camera (CF 20 DXC air, Kappa Mess-
technik, Gleichen, Germany) on an inverted microscope (Nikon, Diaphot
300,Tokyo, Japan). All pictures were taken under the same conditions with
50magni¢cation. The area and intensity of the naphthol red signal was
quanti¢ed on an image analysis system (PicEd Cora, Jomesa, Munich,
Germany). The program parameters were set up so that the control
sections without incubation with primary antibody had less than 1%
staining. Measurements were taken from three di¡erent sections on the
same slide. The expression level was estimated as the percentage of
naphthol red stained area compared to the total measured area in
epidermis. The average values and standard deviations were taken from
triplicate readings. The quanti¢cation of the expression of CK16 and
TGF-b type II receptor in epidermis was performed in the same way.
Confocal microscopy of immunohistochemical staining with
£uorescence For £uorescence labeling, the secondary antibody was
Cy5-conjugated goat antirabbit IgG (Hþ L) (Jackson ImmunoResearch
Laboratories, West Grove, PA). The secondary antibodies had been tested
for minimal cross-reaction to human, mouse, and rat serum proteins.
Sections were mounted with FluorSave (Calbiochem, Darmstadt,
Germany). Confocal microscopy was performed with a Zeiss Confocal
Figure1. Upregulation of TGF-b type II receptor after exposure of
human skin organ cultures to b-endorphin. The skin culture samples
were incubated either without (a) or with (b) 62 nM b-endorphin for 48 h.
The TGF-b type II receptor expression was determined on depara⁄nized
sections using naphthol red as substrate of the alkaline phosphatase. Scale
bar: 50 mm.
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Laser Scanning Microscope LSM 510, inverted Axiovert 100 M (Carl Zeiss
AG, Jena, Germany). It operates in the sequential acquisition mode to
exclude cross-talk between channels. The 488 (for Cy2), 568 (for Cy3),
and 647 (for Cy5) excitation lines were used and the optics were a Zeiss
Plan-Neo£uar 40 oil immersion objective with a numerical aperture of
1.3. Optical sections of 0.9 mm thickness were scanned through the z plane
of the sample. The three-dimensional reconstruction was done with the
‘‘Full 3D’’ function of the Imaris 3.0 software (Bitplane, Zˇrich,
Switzerland). Images were quanti¢ed using the IMARIS statistic software
package.
RESULTS
TGF-b type II receptor and CK16 expression in human
epidermis is upregulated by b-endorphin Figure 1 shows
the massive overexpression of TGF-b type II receptor after
exposure of human skin organ cultures to 62 nM b-endorphin
(Fig 1b) compared to skin only exposed to the medium (Fig
1a). In Fig 2 we correlate the CK16 overexpression in epidermis
at various concentrations of b-endorphin with the expression of
TGF-b type II receptor. Interestingly these two expression
patterns look exactly the same, which means that with
increasing concentrations of b-endorphin the expressions of
Figure 2. Upregulation of TGF-b type II receptor and CK16 after
exposure of human skin organ cultures to b-endorphin. Skin culture
samples were exposed to 0^125 nm b-endorphin for 48 h, and TGF-b type
II receptor expression or CK16 expression was quanti¢ed by measuring the
intensity of naphthol red using triplicates of digital images from three dif-
ferent regions of the same skin culture sample. The bars represent percen-
tage of red stained area compared with the total epidermal area measured
on three samples7SD.
Figure 3. Blocking of the upregulation of TGF-b type II expression
induced by b-endorphin in human skin organ cultures.The skin or-
gan cultures were incubated for 48 h with 60 nM b-endorphin in the pre-
sence or absence of 80 nM polyclonal guinea pig anti-m-opiate receptor
antibody or 80 nM naltrexone. The bars represent percentage of red stained
area compared with the total epidermal area measured on three sam-
ples7SD.
Figure 4. Normal expression of l-opiate receptor at the wound
margins of acute wounds. The expression of m-opiate receptor in biop-
sies of normal skin (a), burn wound (b), and abrasio (c) was determined on
depara⁄nized sections using naphthol red as substrate of the alkaline phos-
phatase and a polyclonal rabbit anti-m-opioid receptor antibody as primary
antibody (see Materials and Methods). Scale bar: 50 mm.
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both TGF-b type II receptor and CK16 increase. Both of these
factors are crucial in wound healing. With addition of
naltrexone the overexpression of TGF-b type II receptor
immunoreactivity could be prevented, suggesting a speci¢c
e¡ect of b-endorphin (Fig 3).
l-Opiate receptors are signi¢cantly less expressed at the
wound margins of chronic wounds compared to acute
wounds In order to test if the e¡ects of b-endorphin on
human epidermis in skin organ cultures is present in clinical
specimens, we stained para⁄n-embedded skin biopsies from the
archives of the Department of Dermatology in Basel with
antibodies for m-opiate receptors. Biopsies from both acute and
chronic wounds were tested. As shown in Fig 2, CK16 is
upregulated in skin organ cultures exposed to the endogenous
ligand b-endorphin. On the other hand b-endorphin
downregulates the expression of m-opiate receptor in the same
skin organ cultures. Therefore we would expect the expression
of the m-opiate receptor on keratinocytes to be downregulated at
the wound margins of chronic wounds, where the keratinocytes
are hyperproliferative and express CK16.We observed exactly this
pattern and our experiments con¢rmed this. In acute wounds
the m-opiate receptor expression is comparable to normal skin
(Fig 4a). As acute wounds we used burn wounds (Fig 4b) and
abrasio (Fig 4c) of epidermis. An abrasio is a removal of
epidermis and upper parts of dermis by trauma or scratching. In
chronic wounds the m-opiate receptor expression is signi¢cantly
downregulated. We de¢ned chronic wounds as wounds that do
not heal normally, for instance ulcus cruris (Fig 5a,b), wounds
on the lower legs derived mostly from chronic venous
hypertension. Wounds in skin previously exposed to irradiation
therapy for underlying cancers also do not heal normally and
can be considered as chronic wounds. The skin exposed to
radiation is called radioderm (Fig 5c). At the wound margins of
this skin the m-opiate receptor is signi¢cantly downregulated
compared to normal skin and epidermis at acute wounds
(Fig 4a). In Fig 6 we show the results of the semiquantitative
analysis of two representative experiments measuring the
m-opiate receptor expression in the epidermis of wound margins
of acute and especially of chronic wounds. It shows clearly the
signi¢cant downregulation of the receptor in chronic wounds.
In confocal microscopy the l-opiate receptor expression in
chronic wounds is downregulated and the expression of the
ligand b-endorphin is upregulated To con¢rm the above
observed downregulation of m-opiate receptor in epidermis at
wound margins of chronic wounds we performed a di¡erent
Figure 5. Dramatic downregulation of the expression of l-opiate
receptor at the wound margins of chronic wounds. The expression
of m-opiate receptor in skin biopsies of ulcus cruris (a, b) and ulcer in radio-
derm (c) was determined on depara⁄nized sections using naphthol red as
substrate of the alkaline phosphatase and a polyclonal rabbit anti-m-opioid
receptor antibody as primary antibody (see Materials and Methods). Scale bar:
50 mm.
Figure 6. Downregulation of l-opiate receptor expression in epi-
dermis at the wound margins of chronic wounds compared to nor-
mal skin and acute wounds.The expression of m-opiate receptor in skin
biopsies from the wound margin of di¡erent acute and chronic wounds
and from normal skin was determined by immunohistochemistry. The
staining was conducted as described in Figs 4 and 5. The points represent
percentage of red stained area compared with the total epidermal area mea-
sured on three di¡erent regions of the slide7SD.
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kind of microscopy using immuno£uorescence instead of
immunohistochemistry. First the experiments con¢rm the
downregulation of m-opiate receptor expression in epidermis at
the wound margin of ulcus cruris (Fig 7b) compared to normal
skin (Fig 7a) and an acute burn wound, also from the lower leg
(Fig 7c).We performed a double staining using at the same time
antibodies against the ligand b-endorphin. As we would expect
we observed at the wound margin of chronic wounds a
remarkable upregulation of expression of the endogenous ligand
b-endorphin (Fig 8b) leading to a downregulation of the
receptor expression. In normal skin we see some b-endorphin
expression (Fig 8a). In acute burn wounds, however (Fig 8c),
we see a slightly higher expression of b-endorphin in
keratinocytes.
DISCUSSION
In this paper we describe how the opiate receptor system a¡ects
epidermal cell growth and di¡erentiation through CK16 and
TGF-b type II receptor. Our previous data have shown that the
expression of CK16 is upregulated by b-endorphin in skin organ
culture experiments (Bigliardi-Qi et al, 2000). We could now
show additionally that this overexpression correlates with the ex-
pression of TGF-b type II receptor. Thus CK16, an important
marker of hyperproliferative di¡erentiation patterns in wound
healing, as well as TGF-b type II receptor are upregulated by
50^100 nM of b-endorphin. These concentrations of ligand could
also downregulate the opiate receptor expression in epidermis,
which is a sign of negative feedback.
Figure 7. Downregulation of l-opiate receptor expression at wound margins of chronic wounds by three-dimensional confocal microscopy.
Three-dimensional confocal micrograph of cryostat sections (50 mm) of normal human skin (a), chronic ulcus cruris (b), and acute burn wounds (c), stained
for m-opiate receptor with Cy-5 £uorophore (blue). The primary antibody is a polyclonal rabbit anti-m-opiate receptor antibody. Scale bar: 50 mm.
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Members of the TGF-b superfamily are critical regulators for
epithelial growth and keratinocyte di¡erentiation. TGF-b med-
iates its biologic e¡ects through three high-a⁄nity cell surface re-
ceptors, the TGF-b type I, type II, and type III receptors, and the
Smad family of transcription factors. The precise role of the type
III receptor in TGF-b signaling remains unclear. Much attention
is put on the role of TGF-b in wound healing. After injury the
expression of type II and I receptors and their ligands were in-
creased in epidermis adjacent to the wound (Gold et al, 1997).
The TGF-b signaling pathway is one of the most important me-
chanisms in the maintenance of epithelial homeostasis.Transgenic
mice that overexpressTGF-b1 in the suprabasal keratinocyte com-
partment showed a 2- to 3-fold increase in epidermal DNA la-
beling index over control mice, in the absence of hyperplasia.
During induction of hyperplasia by 12-tetradecanoyl-phorbol-
13-acetate TGF-b receptor I levels remained relatively constant,
and TGF-b receptor II expression was strongly induced (Cui
et al, 1995). Transduction of TGF-b signaling depends on the
phosphorylation and activation of Smad proteins. Transgenic
mice that overexpress Smad2 in epidermis have delayed hair
growth, underdeveloped ears, and severe thickening of the epi-
dermis. These abnormal phenotypes are due to increased prolif-
eration of the basal epidermal cells and abnormalities in the
program of keratinocyte di¡erentiation (Ito et al, 2001). From our
Figure 8. Upregulation of b-endorphin expression at wound margins of chronic wounds by three-dimensional confocal microscopy. Three-
dimensional confocal micrograph of cryostat sections (50 mm) of normal human skin (a), chronic ulcus cruris (b), and acute burn wounds (c), stained for b-
endorphin with Cy-2 £uorophore (green). The primary antibody is a polyclonal mouse anti-b-endorphin antibody. Scale bar: 50 mm.
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skin organ culture experiments, in which b-endorphin upregu-
lates TGF-b type II receptor and CK16, we could speculate that
the opioid ligands also control the di¡erentiation pattern and the
expression of TGF receptors in acute and chronic wounds. There-
fore the opioid receptor system in epidermis is involved in skin
homeostasis through the TGF receptor system. Furthermore, as
deletion of the TGF-b type II receptor accelerates skin carcino-
genesis (Wang, 2001) we could hypothesize that the opiate recep-
tor system in epidermis is involved in skin cancers as well. Indeed,
we have previously observed a signi¢cant downregulation of the
m-opiate receptor in basal cell carcinoma (Bigliardi-Qi et al, 1999).
In nature stress is often associated with possible wounding dur-
ing a ¢ght or £eeing. During stress the POMC peptides adreno-
corticotropin and b-endorphin are released locally. Therefore it is
natural that the locally released b-endorphin controls the pain in
the periphery. It is known that the opioid peptides have impor-
tant in£uences on immune cells and keratinocytes besides the
pain control and in the central nervous system. The role of li-
gands of the opiate receptor system in wound healing has been
previously described. The local application in rats of the opioid
peptide dalargin, a leu-enkephalin analog, induces ¢broblast pro-
liferation (3-fold increase in the mitotic index) and growth of ca-
pillaries, accelerates the maturation of granulation tissue and the
epithelization of the defect, and considerably reduces the period
of healing of skin wounds. The stimulating action of dalargin is
associated with its e¡ect on the microcirculation system and the
activation of the macrophage^¢broblast interaction. Possessing
the triggering mechanism, the drug induces a cascade of in£am-
matory-reparative reactions, which reduce the duration of all
healing stages (Shekhter et al, 1988; Kohl et al, 1989). It has been
found that the m-opiate receptor ligand b-endorphin has an im-
portant role in limb regeneration in nonmammalian vertebrates
(Vethamany-Globus et al, 1983). Another group (Soledad Cepeda
et al, 1993) examined the interactions between exogenous opioid
analgesia and endogenous opioid generation at a site of burn-in-
duced tissue injury. b-Endorphin was measured in wound £uid
withdrawn from subcutaneous wire mesh chambers beneath the
site of a 3%^5% surface area burn in rats.The concentration of b-
endorphin rose above baseline at 1, 2, and 4 h postburn, and then
returned to baseline at 24 h. Systemic opioid treatment produced
analgesia (by tail £ick latency testing) but did not reduce intra-
chamber hormone responses. Thus local b-endorphin responses
at the site of thermal injury are regulated di¡erently from sys-
temic pituitary^adrenal responses. In humans b-endorphin con-
centrations in plasma are signi¢cantly increased in burn patients
as well, and the amount of b-endorphin in plasma correlated po-
sitively with the extent of the burn areas (r¼ 0.576) (Xue, 1991). It
is hypothesized that the elevation of circulating b-endorphin le-
vels causes a modulation of the immune system after traumatic
injury (Levy et al, 1986). Because keratinocytes are able to produce
b-endorphin (Wintzen et al, 1995; Zanello et al, 1999), we postulate
that the elevated b-endorphin concentrations in plasma and espe-
cially wound £uid not only arise from the central nervous system
but also are produced in the skin by keratinocytes locally after
injury.
The best studied role of opioids is in pain control, in which
opioids are known to inhibit neurotransmitter release from dorsal
root ganglion projections in the dorsal horn of the spinal cord
(Zhang et al, 1998). But there are several studies indicating that
opiate-induced analgesia is due to a peripheral mechanism, be-
sides its well recognized central mechanism of action (Ferreira
and Nakamura, 1979; Joris et al, 1987). The local administration of
opioid peptides seems to relieve pain (Twillman et al, 1999), an-
other important and distressing symptom in chronic wounds.
The pain could also interfere with the wound healing directly.
Our results show a downregulation of m-opiate receptor in
chronic wounds and a normal epidermal expression of the recep-
tor at the wound margin of acute wounds. High concentrations
of b-endorphin downregulate the expression of the receptor in a
negative feedback mechanism (Bigliardi-Qi et al, 2000); therefore
we would expect high expressions of the ligand in chronic
wounds, and indeed in chronic wounds the expression of b-en-
dorphin is markedly increased. In acute wounds we observe
slightly more expression of b-endorphin compared to normal
skin, but this does not lead to a downregulation of the receptor.
This suggests that in acute wounds the ligand and the m-opiate
receptor are expressed in a balanced level, which leads to more
expression of CK16 and TGF-b type II receptor. This balance is
disturbed in chronic wounds, however, where the ligand is
highly overexpressed and the receptor is therefore downregu-
lated; this leads to changes in di¡erentiation and expression of
growth factors and their receptors that are involved in impaired
wound healing in chronic wounds. All of these e¡ects together
underline the importance of studying neuropeptides, especially
opiate receptor ligands in wound healing, which might lead to
new therapy of wounds. Ligands of the opiate receptors can be
used not only locally for pain control in wounds but also to im-
prove the process of wound healing and reepithelization and to
enhance hypertrophic scars through upregulation of the TGF-b
system.
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